RxDoctor Payments Data

Tehmina Bajwa, MD

Family Medicine · North Aurora, ILNPI 1922083476

Payments from drug & device makers

$1,850in general payments, 2019–2025

Across 55 payments — averaging $33.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$442
  • AstraZeneca$381
  • Sanofi-aventis U.S. LLC$220
  • Edwards Lifesciences$180
  • Bayer$123
  • Medtronic$101
  • plus $403 from 7 others

What the payments were for

  • Food & beverage$1,83899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,850 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$160,888
Medicare patients
320
Services billed
1,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate77$104,640
OzempicSemaglutide72$99,525
JardianceEmpagliflozin68$87,761
FarxigaDapagliflozin Propanediol96$67,770
EliquisApixaban51$41,566
XareltoRivaroxaban35$35,540
MyrbetriqMirabegron30$25,383
Lantus SolostarInsulin Glargine,hum.Rec.Anlog93$21,397
MounjaroTirzepatide19$20,020
Spiriva HandihalerTiotropium Bromide15$19,647
Advair HfaFluticasone Propion/Salmeterol37$17,130
TrulicityDulaglutide11$16,101
Tresiba Flextouch U-100Insulin Degludec14$15,427
LinzessLinaclotide23$13,970
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$8,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$442$99,52572 claims
AstraZenecaFarxiga$381$67,77096 claims
PfizerEliquis$52$41,56651 claims
Lilly USA, LLCMounjaro, Trulicity$97$36,12030 claims
Johnson & JohnsonXarelto$97$35,54035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in North Aurora

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →